Mendota Financial Group LLC Lowers Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mendota Financial Group LLC reduced its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 18.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,222 shares of the medical equipment provider’s stock after selling 282 shares during the period. Mendota Financial Group LLC’s holdings in Lantheus were worth $109,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in shares of Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after buying an additional 32,551 shares during the period. Moloney Securities Asset Management LLC purchased a new stake in shares of Lantheus in the 3rd quarter valued at approximately $1,066,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Lantheus in the 3rd quarter valued at $25,955,000. Van ECK Associates Corp lifted its position in shares of Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after purchasing an additional 21,604 shares during the last quarter. Finally, Swedbank AB grew its stake in shares of Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after purchasing an additional 125,843 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Down 1.3 %

Shares of NASDAQ:LNTH opened at $94.65 on Tuesday. The company has a 50-day moving average price of $89.98 and a 200 day moving average price of $99.78. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The company has a market cap of $6.58 billion, a P/E ratio of 15.75 and a beta of 0.46.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities lowered their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Finally, Truist Financial reiterated a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.